Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ribociclib vs Chemotherapy in Visceral Metastatic Breast Cancer
NCT03905343Phase 3Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Jun 2019
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of ribociclib in breast cancer (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Quality of life-adjusted early disease control at 12 weeks. Started Jun 2019; status: terminated.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03905343.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03905343.